|
12.
|
|
9 p, 821.4 KB |
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma : Final Results of a Randomized Phase III Study
/
Kwak, Larry W. (Comprehensive Cancer Center, Duarte) ;
Sancho, Juan Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cho, Seok Goo (The Catholic University of Korea, Seoul, South Korea) ;
Nakazawa, Hideyuki (Shinshu University School of Medicine, Nagano, Japan) ;
Suzumiya, Junji (Shimane University Hospital, Innovative Cancer Center/Oncology-Hematology, Izumo, Japan) ;
Tumyan, Gayane (Division of Hematology and Bone Marrow Transplantation, Blokhin Russian Cancer) ;
Kim, Jin Seok (Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea) ;
Menne, Tobias (Newcastle University, UK) ;
Mariz, José (Instituto Português de Oncología do Porto) ;
Ilyin, Nikolai (Ministry of Health of the Russian Federation) ;
Jurczak, Wojciech (Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland) ;
Lopez Martinez, Aurelio (Hospital Arnau de Vilanova (València)) ;
Samoilova, Olga (Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russia) ;
Zhavrid, Edvard (N. N. Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Belarus) ;
Yañez Ruiz, Eduardo (Universidad de la Frontera, Temuco, Chile) ;
Trneny, Marek (Charles University, Czech Republic) ;
Popplewell, Leslie (Toni Stephenson Lymphoma Cancer Center and Department of Hematology and Hematopoietic Cell Transplantation, Duarte, CA) ;
Ogura, Michinori (Kasugai Municipal Hospital, Aichi 486-8510, Japan.) ;
Kim, Wong Seog (Sungkyunkwan University School of Medicine, Seoul, South Korea) ;
Lee, Sang Joon (Celltrion. Inc, South Korea) ;
Kim, Sung Hyun (Celltrion. Inc, South Korea) ;
Ahn, Keum Young (Celltrion. Inc, South Korea) ;
Buske, Christian (University Hospital of Ulm, Germany)
Introduction: This double-blind, parallel-group, active-controlled phase III trial (NCT02260804) assessed CT-P10 and rituximab safety and efficacy in patients with previously untreated low-tumor-burden follicular lymphoma (LTBFL), including after a single switch from rituximab to CT-P10. [...]
2022 -  10.1016/j.clml.2021.08.005
Clinical Lymphoma, Myeloma & Leukemia, Vol. 22 Núm. 2 (february 2022) , p. 89-97
|
|
|
16.
|
|
16 p, 3.8 MB |
Genetic and phenotypic attributes of splenic marginal zone lymphoma
/
Bonfiglio, Ferdinando (Institute of Oncology Research, Bellinzona, Switzerland) ;
Bruscaggin, Alessio (Institute of Oncology Research, Bellinzona, Switzerland) ;
Guidetti, Francesca (Institute of Oncology Research, Bellinzona, Switzerland) ;
Terzi di Bergamo, Lodovico (Institute of Oncology Research, Bellinzona, Switzerland) ;
Faderl, Martin (Institute of Oncology Research, Bellinzona, Switzerland) ;
Spina, Valeria (Institute of Oncology Research, Bellinzona, Switzerland) ;
Condoluci, Adalgisa (Institute of Oncology Research, Bellinzona, Switzerland) ;
Bonomini, Luisella (International Extranodal Lymphoma Study Group, Bellinzona, Switzerland) ;
Forestieri, Gabriela (Institute of Oncology Research, Bellinzona, Switzerland) ;
Koch, Ricardo (Institute of Oncology Research, Bellinzona, Switzerland) ;
Piffaretti, Deborah (Institute of Oncology Research, Bellinzona, Switzerland) ;
Pini, Katia (Institute of Oncology Research, Bellinzona, Switzerland) ;
Pirosa, Maria Cristina (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Cittone, Micol Giulia (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Arribas, Alberto (Lymphoma Genomics, Institute of Oncology Research, Bellinzona, Switzerland) ;
Lucioni, Marco (Fondazione IRCCS Policlinico San Matteo and Università degli Studi di Pavia, Pavia, Italy) ;
Ghilardi, Guido (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.) ;
Wu, Wei (Institute of Oncology Research, Bellinzona, Switzerland) ;
Arcaini, Luca (University of Pavia, Pavia, Italy.) ;
Baptista, Maria Joao (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bastidas-Mora, Gabriela (Hospital Clínic i Provincial de Barcelona) ;
Bea, Sílvia (Hospital Clínic i Provincial de Barcelona) ;
Boldorini, Renzo (University of Eastern Piedmont, Novara, Italy) ;
Broccoli, Alessandro (IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy.) ;
Buehler, Marco Matteo (University Hospital Zurich, Switzerland) ;
Canzonieri, Vincenzo (Pathology Unit, CRO Aviano National Cancer Institute, Aviano, Italy) ;
Cascione, Luciano (Institute of Oncology Research, Bellinzona, Switzerland) ;
Ceriani, Luca (Clinic of Nuclear Medicine and PET-CT Centre, Imaging Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Cogliatti, Sergio (Institute of Pathology, Kantonsspital St Gallen, St Gallen, Switzerland) ;
Corradini, Paolo (Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy) ;
Derenzini, Enrico (European Institute of Oncology (IEO) IRCCS, Milan, Italy) ;
Devizzi, Liliana (Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy) ;
Dietrich, Sascha (University Hospital Heidelberg, Germany) ;
Elia, Angela Rita (Institute of Oncology Research, Bellinzona, Switzerland) ;
Facchetti, Fabio (Pathology Unit, Spedali Civili, Brescia, Italy) ;
Gaidano, Gianluca (University of Eastern Piedmont, Novara, Italy) ;
Garcia, Juan Fernando (MD Anderson Cancer Center, Madrid) ;
Gerber, Bernhard (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Ghia, Paolo (IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy) ;
Gomes da Silva, Maria (Instituto Português de Oncologia de Lisboa, Portugal) ;
Gritti, Giuseppe (Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy) ;
Guidetti, Anna (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy) ;
Hitz, Felicitas (Kantonsspital St Gallen, St Gallen, Switzerland) ;
Inghirami, Giorgio (Weill Cornell Medical College, New York) ;
Ladetto, Marco (Azienda Ospedaliera SS Antonio e Biagio, Alessandria, Italy) ;
Lopez-Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ;
Lucchini, Elisa (Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy) ;
Maiorana, Antonino (Universitá degli Studi di Modena e Reggio Emilia, Modena, Italy) ;
Marasca, Roberto (University of Modena and Reggio Emilia, Modena, Italy) ;
Matutes, Estella (Hospital Clínic i Provincial de Barcelona) ;
Meignin, Veronique (Saint Louis Hospital, Paris, France) ;
Merli, Michele (University of Insubria and ASST Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy) ;
Moccia, Alden (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Mollejo, Manuela (Hospital Virgen de la Salud (Toledo)) ;
Montalban, Carlos (MD Anderson Cancer Center, Madrid) ;
Novak, Urban (University of Bern, Bern, Switzerland) ;
Oscier, David Graham (University Hospitals Dorset, Bournemouth, United Kingdom) ;
Passamonti, Francesco (University of Insubria) ;
Piazza, Francesco (Ospedale Universitario di Padova, Italy) ;
Pizzolitto, Stefano (General Hospital S Maria della Misericordia, Udine, Italy) ;
Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy) ;
Sabattini, Elena (University of Bologna, Italy) ;
Salles, Gilles (Université de Lyon, France) ;
Santambrogio, Elisa (Candiolo Cancer Institute (FPO-IRCCS), Candiolo, Turin, Italy) ;
Scarfò, Lydia (IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy) ;
Stathis, Anastasios (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Stüssi, Georg (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Geyer, Julia T. (Weill Cornell Medical College, New York) ;
Tapia, G. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Tarella, Corrado (European Institute of Oncology (IEO) IRCCS, Milan, Italy) ;
Thieblemont, Catherine (Université de Paris, France) ;
Tousseyn, Thomas (University Hospitals Leuven, Belgium) ;
Tucci, Alessandra (Spedali Civili, Brescia, Italy.) ;
Vanini, Giorgio (University of Bern, Switzerland) ;
Visco, Carlo (University of Verona, Italy) ;
Vitolo, Umberto (Candiolo Cancer Institute (FPO-IRCCS), Candiolo, Turin, Italy) ;
Walewska, Renata (University Hospitals Dorset, Bournemouth, United Kingdom) ;
Zaja, Francesco (Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy) ;
Zenz, Thorsten (University Hospital Zurich, Switzerland) ;
Zinzani, Pier Luigi (Università di Bologna, Italy) ;
Khiabanian, Hossein (Rutgers University, New Brunswick) ;
Calcinotto, Arianna (Institute of Oncology Research, Bellinzona, Switzerland) ;
Bertoni, Francesco (Institute of Oncology Research, Bellinzona, Switzerland) ;
Bhagat, Govind (Columbia University, New York, USA) ;
Campo, Elias (Hospital Clínic i Provincial de Barcelona) ;
de Leval, Laurence (Institut Universitaire de Pathologie, Lausanne, Switzerland) ;
Dirnhofer, Stefan (University Hospital Basel (Basilea, Suïssa)) ;
Pileri, Stefano A. (European Institute of Oncology IRCCS, Milan, Italy) ;
Piris, Miguel Angel (Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Madrid) ;
Traverse-Glehen, Alexandra (Centre Hospitalier Lyon Sud, Lyon, France) ;
Tzankov, Alexander (University Hospital Basel (Basilea, Suïssa)) ;
Paulli, Marco (Fondazione IRCCS Policlinico San Matteo and Università degli Studi di Pavia, Italy) ;
Ponzoni, Maurilio (Ateneo Vita-Salute San Raffaele University and Pathology Unit San Raffaele Scientific Institute, Milan, Italy) ;
Mazzucchelli, Luca (antonal Institute of Pathology, Locarno, Switzerland) ;
Cavalli, Franco (Institute of Oncology Research, Bellinzona, Switzerland; and.) ;
Zucca, Emanuele (International Extranodal Lymphoma Study Group, Bellinzona, Switzerland) ;
Rossi, Davide (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Universitat Autònoma de Barcelona
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways and surrounding microenvironments are diverse. [...]
2022 - 10.1182/blood.2021012386
Blood, Vol. 139 Núm. 5 (february 2022) , p. 732-747
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
